Bank of New York Mellon Corp Has $25.99 Million Stock Position in Haleon PLC Sponsored ADR $HLN

Bank of New York Mellon Corp reduced its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 2.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,596,454 shares of the company’s stock after selling 56,865 shares during the quarter. Bank of New York Mellon Corp owned about 0.06% of Haleon worth $25,990,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in HLN. Parkside Financial Bank & Trust grew its holdings in Haleon by 101.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after purchasing an additional 1,433 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Haleon by 428.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after purchasing an additional 5,124 shares in the last quarter. Assetmark Inc. grew its stake in shares of Haleon by 26.6% in the 4th quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock valued at $60,000 after buying an additional 1,252 shares during the period. Finally, Atlantic Union Bankshares Corp grew its stake in shares of Haleon by 69.4% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,264 shares of the company’s stock valued at $63,000 after buying an additional 2,567 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HLN. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Zacks Research lowered Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of HLN stock opened at $9.95 on Tuesday. The firm has a 50-day moving average of $9.37 and a 200-day moving average of $9.85. The company has a market cap of $43.80 billion, a P/E ratio of 25.50, a P/E/G ratio of 2.26 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. Haleon PLC Sponsored ADR has a one year low of $8.65 and a one year high of $11.28.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.